See more : Davide Campari-Milano N.V. (CPR.MI) Income Statement Analysis – Financial Results
Complete financial analysis of Cyclacel Pharmaceuticals, Inc. (CYCC) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Cyclacel Pharmaceuticals, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- ST Energy Transition I Ltd. (STET-UN) Income Statement Analysis – Financial Results
- Polyard Petroleum International Group Limited (8011.HK) Income Statement Analysis – Financial Results
- Verastem, Inc. (0LOV.L) Income Statement Analysis – Financial Results
- Global Vectra Helicorp Limited (GLOBALVECT.BO) Income Statement Analysis – Financial Results
- Pine Technology Acquisition Corp. (PTOC) Income Statement Analysis – Financial Results
Cyclacel Pharmaceuticals, Inc. (CYCC)
About Cyclacel Pharmaceuticals, Inc.
Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's development programs include fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and CYC140, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced leukemias and solid tumors. Its development programs also comprise Sapacitabine, a novel nucleoside analog that is orally available prodrug of CNDAC, which is in Phase 1/2 clinical trials to treat acute myeloid leukemia and myelodysplastic syndrome; and seliciclib, a CDK inhibitor that is in Phase 2 investigator-sponsored trials (IST) for Cushing's disease, as well as in Phase 1/2 IST for the treatment for advanced rheumatoid arthritis. The company has a clinical collaboration agreement with the University of Texas MD Anderson Cancer Center to clinically evaluate the safety and efficacy of three cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemias, acute myeloid leukemias, myelodysplastic syndromes, and other advanced leukemias. Cyclacel Pharmaceuticals, Inc. is headquartered in Berkeley Heights, New Jersey.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 420.00K | 0.00 | 0.00 | 0.00 | 0.00 | 150.00K | 0.00 | 843.00K | 1.94M | 1.73M | 1.08M | 69.00K | 699.00K | 686.00K | 911.00K | 877.00K | 129.00K | 387.00K | 813.00K | 62.00K | 170.00K | 0.00 | 30.00K | 98.00K |
| Cost of Revenue | 0.00 | 32.00K | 43.00K | 20.00K | 20.00K | 4.33M | 32.00K | 9.48M | 12.38M | 18.28M | 11.28M | 6.59M | 360.00K | 418.00K | 545.00K | 429.00K | 19.57M | 21.21M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 420.00K | -32.00K | -43.00K | -20.00K | -20.00K | -4.18M | -32.00K | -8.63M | -10.44M | -16.54M | -10.19M | -6.52M | 339.00K | 268.00K | 366.00K | 448.00K | -19.44M | -20.82M | 813.00K | 62.00K | 170.00K | 0.00 | 30.00K | 98.00K |
| Gross Profit Ratio | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% | -2,784.67% | 0.00% | -1,024.20% | -536.93% | -954.04% | -940.31% | -9,453.62% | 48.50% | 39.07% | 40.18% | 51.08% | -15,069.77% | -5,379.33% | 100.00% | 100.00% | 100.00% | 0.00% | 100.00% | 100.00% |
| Research & Development | 19.16M | 20.27M | 15.48M | 4.76M | 4.66M | 4.33M | 4.24M | 9.48M | 12.38M | 18.28M | 11.28M | 6.59M | 9.21M | 6.41M | 9.77M | 18.87M | 10.00K | 231.00K | 13.77M | 19.70M | 13.69M | 14.66M | 14.70M | 11.26M |
| General & Administrative | 6.72M | 7.38M | 7.46M | 5.88M | 5.02M | 5.37M | 5.25M | 5.52M | 5.73M | 5.89M | 7.78M | 8.58M | 7.52M | 10.12M | 8.54M | 15.35M | 11.54M | 12.32M | 9.67M | 6.88M | 4.32M | 0.00 | 5.20M | 2.40M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 20.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 6.72M | 7.38M | 7.46M | 5.88M | 5.02M | 5.37M | 5.25M | 5.52M | 5.75M | 5.89M | 7.78M | 8.58M | 7.52M | 10.12M | 8.54M | 15.35M | 11.54M | 12.32M | 9.67M | 6.88M | 4.32M | 4.98M | 5.20M | 2.40M |
| Other Expenses | 0.00 | 1.30M | 144.00K | 891.00K | 231.00K | 682.00K | 949.00K | 0.00 | 12.13K | 0.00 | 0.00 | 0.00 | 360.00K | 6.73M | 911.00K | 8.85M | 21.11M | 0.00 | 7.06M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 25.87M | 27.66M | 22.94M | 10.64M | 9.68M | 9.70M | 9.49M | 14.99M | 18.13M | 24.17M | 19.06M | 15.17M | 16.73M | 16.53M | 18.30M | 34.22M | 11.54M | 12.32M | 30.50M | 26.57M | 18.01M | 19.64M | 19.91M | 13.66M |
| Cost & Expenses | 25.87M | 27.66M | 22.94M | 10.64M | 9.68M | 9.70M | 9.49M | 14.99M | 18.13M | 24.17M | 19.06M | 15.17M | 17.09M | 16.95M | 18.85M | 34.65M | 31.11M | 33.52M | 30.50M | 26.57M | 18.01M | 19.64M | 19.91M | 13.66M |
| Interest Income | 266.00K | 210.00K | 16.00K | 42.00K | 224.00K | 331.00K | 118.00K | 37.00K | 9.00K | 6.00K | 13.00K | 22.00K | 45.00K | 37.00K | 102.00K | 1.38M | 3.55M | 2.33M | 960.00K | 421.00K | 149.00K | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 43.00K | 177.00K | 318.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 31.00K | 32.00K | 43.00K | 20.00K | 20.00K | 29.00K | 32.00K | 133.00K | 210.00K | 174.00K | 70.00K | 60.00K | 241.00K | 457.00K | 668.00K | 1.86M | 299.00K | 1.10M | 1.55M | 1.31M | 929.00K | 0.00 | 0.00 | -621.00K |
| EBITDA | -25.42M | -27.62M | -22.69M | -10.62M | -9.66M | -9.52M | -9.46M | -14.02M | -15.96M | -22.26M | -17.90M | -15.05M | -15.57M | -16.18M | -19.67M | -39.96M | -24.75M | -30.13M | -19.45M | -24.48M | -16.91M | -19.64M | -19.88M | -14.18M |
| EBITDA Ratio | -6,052.86% | 0.00% | 0.00% | 0.00% | 0.00% | -6,305.33% | 0.00% | -1,718.74% | -817.13% | -1,281.37% | -1,656.92% | -21,782.61% | -2,303.58% | -2,299.13% | -1,957.85% | -3,481.53% | -24,993.80% | -8,165.89% | -2,551.54% | -39,482.26% | -9,945.29% | 0.00% | -66,250.00% | -14,472.45% |
| Operating Income | -25.45M | -27.66M | -22.94M | -10.64M | -9.68M | -9.55M | -9.49M | -14.15M | -16.17M | -22.44M | -17.97M | -15.10M | -16.39M | -16.27M | -18.30M | -42.20M | -32.54M | -33.36M | -29.69M | -26.51M | -17.84M | -19.64M | -19.88M | -13.56M |
| Operating Income Ratio | -6,060.24% | 0.00% | 0.00% | 0.00% | 0.00% | -6,365.33% | 0.00% | -1,678.53% | -831.79% | -1,293.94% | -1,658.12% | -21,888.41% | -2,344.49% | -2,371.14% | -2,009.22% | -4,811.63% | -25,222.48% | -8,620.67% | -3,651.91% | -42,761.29% | -10,492.35% | 0.00% | -66,250.00% | -13,838.78% |
| Total Other Income/Expenses | -98.00K | 1.74M | 204.00K | 955.00K | 556.00K | 923.00K | 1.03M | 376.00K | -316.00K | -212.00K | 6.09M | -4.00K | 580.00K | 245.00K | -2.58M | -8.36M | 4.89M | 1.63M | 827.00K | 1.31M | -1.00K | 0.00 | 19.88M | 621.00K |
| Income Before Tax | -25.55M | -25.92M | -22.73M | -9.68M | -9.13M | -8.63M | -8.46M | -13.77M | -16.49M | -22.65M | -11.88M | -15.11M | -15.81M | -16.68M | -20.52M | -42.14M | -26.09M | -31.50M | -37.09M | -27.24M | -17.84M | 0.00 | 0.00 | -12.94M |
| Income Before Tax Ratio | -6,083.57% | 0.00% | 0.00% | 0.00% | 0.00% | -5,750.00% | 0.00% | -1,633.93% | -848.05% | -1,306.17% | -1,095.94% | -21,894.20% | -2,261.52% | -2,431.20% | -2,252.25% | -4,804.45% | -20,227.91% | -8,140.31% | -4,561.87% | -43,933.87% | -10,492.94% | 0.00% | 0.00% | -13,205.10% |
| Income Tax Expense | -3.00M | -4.72M | -3.85M | -1.24M | -1.30M | -1.34M | -993.00K | -1.98M | -2.14M | -3.24M | -1.67M | -1.35M | -565.00K | -657.00K | -948.00K | -1.75M | -2.04M | -2.25M | -274.00K | 13.08M | 620.00K | 19.45M | 19.51M | 0.00 |
| Net Income | -22.56M | -21.20M | -18.89M | -8.45M | -7.83M | -7.29M | -7.47M | -11.79M | -14.34M | -19.39M | -10.15M | -13.19M | -15.24M | -16.02M | -19.57M | -40.39M | -24.05M | -29.26M | -29.42M | -39.59M | -18.46M | -19.45M | -19.51M | -12.94M |
| Net Income Ratio | -5,370.24% | 0.00% | 0.00% | 0.00% | 0.00% | -4,858.67% | 0.00% | -1,398.70% | -737.76% | -1,118.05% | -936.62% | -19,110.14% | -2,180.69% | -2,335.42% | -2,148.19% | -4,605.02% | -18,645.74% | -7,560.21% | -3,618.20% | -63,851.61% | -10,857.06% | 0.00% | -65,040.00% | -13,205.10% |
| EPS | -26.75 | -32.23 | -31.74 | -34.86 | -143.88 | -12.05 | -19.58 | -68.85 | -105.72 | -211.93 | -160.75 | -440.40 | -509.10 | -711.22 | -1.48K | -3.32K | -2.03K | -3.67K | -7.42K | -5.35K | -2.10K | -4.91K | -4.92K | -3.27K |
| EPS Diluted | -26.75 | -32.23 | -31.74 | -34.86 | -143.88 | -12.05 | -19.58 | -68.85 | -105.72 | -211.93 | -160.75 | -440.40 | -509.10 | -711.22 | -1.48K | -3.32K | -2.03K | -3.67K | -7.42K | -5.35K | -2.10K | -4.21K | -4.22K | -2.80K |
| Weighted Avg Shares Out | 850.82K | 657.62K | 595.08K | 242.23K | 54.41K | 604.71K | 381.56K | 171.25K | 135.65K | 91.48K | 63.16K | 29.94K | 29.94K | 22.53K | 13.21K | 12.16K | 11.83K | 7.97K | 3.96K | 7.40K | 8.79K | 3.96K | 3.96K | 3.96K |
| Weighted Avg Shares Out (Dil) | 850.82K | 657.62K | 595.08K | 242.23K | 54.41K | 604.71K | 381.56K | 171.25K | 135.65K | 91.48K | 63.16K | 29.94K | 29.94K | 22.53K | 13.21K | 12.16K | 11.83K | 7.97K | 3.96K | 7.40K | 8.79K | 4.62K | 4.62K | 4.62K |
Cyclacel Pharmaceuticals to Release First Quarter 2024 Financial Results
BERKELEY HEIGHTS, N.J., May 08, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, will announce first quarter 2024 financial results on Tuesday,...
Cyclacel Pharmaceuticals Announces Closing of $8.0 Million Private Placement Priced At-The-Market Under NASDAQ Rules
BERKELEY HEIGHTS, N.J., May 02, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced that it has closed its previously announced...
Why Is Cyclacel Pharmaceuticals (CYCC) Stock Up 46% Today?
Cyclacel Pharmaceuticals (NASDAQ: CYCC ) stock is rocketing higher on Tuesday after the clinical-stage biopharmaceutical company withdrew a proposed public offering. A filing with the Securities and Exchange Commission (SEC) has the company withdrawing its proposed public offering filed in March.
Cyclacel Pharmaceuticals Announces $8.0 Million Private Placement Priced At-The-Market Under Nasdaq Rules
BERKELEY HEIGHTS, N.J., April 30, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced that it has entered into definitive agreements...
Cyclacel Pharmaceuticals to Present New Clinical Data at 2024 ASCO Annual Meeting Highlighting Fadraciclib's Potential as a Precision Medicine for Cancer
- New clinical, PK and PD data from novel CDK2/9 inhibitor fadraciclib monotherapy studies support ongoing development program in patients with solid tumors and lymphoma -
Cyclacel Pharmaceuticals, Inc. (CYCC) Q4 2023 Earnings Call Transcript
Cyclacel Pharmaceuticals, Inc. (CYCC) Q4 2023 Earnings Call Transcript
Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
– On Track to Start Oral Fadraciclib Phase 2 Proof of Concept in 1H 2024 – – Expect to Report Final Data from Fadraciclib 065-101 Dose Escalation – – Oral Plogosertib Preclinical Data Support Precision Medicine Strategy in ARID1A- and SMARCA-Mutated Cancers –...
Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2023 Financial Results
BERKELEY HEIGHTS, N.J., March 13, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, will announce fourth quarter and full year 2023 financial...
Cyclacel Pharmaceuticals Announces Preclinical Proof-of-Concept Data for Fadraciclib to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2024
Data support ongoing development program of novel CDK2/9 inhibitor fadraciclib in patients with solid tumors and lymphoma Data support ongoing development program of novel CDK2/9 inhibitor fadraciclib in patients with solid tumors and lymphoma
Cyclacel Pharmaceuticals Announces Receipt of $2.9 Million R&D Tax Credit
BERKELEY HEIGHTS, N.J., March 06, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, announced that it received £2.3 million (approximately $2.9 million)...
Source: https://incomestatements.info
Category: Stock Reports